Company intelligence / Profile preview
Lactiga
North Brunswick, New Jersey, USAlactiga.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lactiga has demonstrated full in vitro neutralization of SARS-CoV‑2 viral components with its lead candidate LCTG‑001. The company’s programs are preclinical but have received NIH funding and are progressing toward IND-enabling studies. Their approach leverages naturally occurring maternal antibodies to address severe mucosal infections in immunocompromised patients, with a focus on rare primary immunodeficiencies and pandemic response applications like COVID‑19.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Novel biologics (antibodies derived from human milk/maternal antibodies)Anti-infectives
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Mount Sinai Health System/Icahn School of Medicine at Mount SinaiMilk banks worldwide for ethical sourcing partnerships
Beyond the preview
Go deeper on Lactiga.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiga.